Search Results
Your search for ,ArM matches 4704 pages
Showing 301 - 350Parker Institute for Cancer Immunotherapy Names New CEO
The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as the new Chief Executive Officer (CEO) of the institute. A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen will take on her...
FDA Approves Perioperative Durvalumab for Muscle-Invasive Bladder Cancer
On March 28, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle-invasive bladder ...
Building and Sharing Dietary Evidence in Cancer Care
Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are often interested in exploring different dietary interventions throughout the cancer continuum. However, concrete...
FDA Approves Cabozantinib for pNET and epNET
Today, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor cabozantinib (Cabometyx) for adult and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors...
Pembrolizumab Plus Chemotherapy: New Standard of Care in Locally Advanced Cervical Cancer?
Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed by pembrolizumab maintenance, as the upfront standard of care for high-risk, locally advanced...
Conundrums in Treating HER2-Positive Early Breast Cancer
Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Conference, Sara A. Hurvitz, MD, FACP, offered insight on common clinical scenarios. Dr. Hurvitz is...
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.” —Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Benefit Suggested for Early Treatment of Advanced-Stage, Very Low–Tumor Burden Follicular Lymphoma
In the phase III JCOG1411/FLORA trial of patients with untreated advanced-stage, very low–tumor burden follicular lymphoma, rituximab induction delayed disease progression to high–tumor burden follicular lymphoma and delayed the initiation of cytotoxic chemotherapy, according to Japanese...
inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology...
Can Adding Antihistamines to Second-Line Therapy Improve Outcomes in Advanced Urothelial Carcinoma?
As reported in the journal Urologic Oncology: Seminars and Original Investigations by Fallara et al, an analysis of individual patient data from the IMvigor210 and IMvigor211 trials revealed that concomitant second-line treatment of locally advanced or metastatic urothelial carcinoma with...
Recent FDA Approvals in Lymphoma and in Rarer Tumors
The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adults with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising ...
Intraperitoneal Paclitaxel Combination Regimen Improves Overall Survival in Advanced Gastric Cancer
Adding intraperitoneal (IP) paclitaxel to standard intravenous (IV) paclitaxel plus S-1 (oral fluoropyrimidine derivative) significantly extended overall survival for patients with gastric cancer peritoneal metastases, according to data presented at the 2025 ASCO Gastrointestinal Cancers...
Exploratory Post Hoc Analysis of DUO-E Reveals Olaparib’s Benefit in Endometrial Cancer Subsets
The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in advanced endometrial cancer. As reported this past year,1 the inclusion of durvalumab reduced the risk...
FDA Approves Pembrolizumab for HER2-Positive Gastric or GEJ Cancer Expressing PD-L1
The U.S. Food and Drug Administration (FDA) has granted traditional approval to the PD-L1 inhibitor pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic...
Techniques for Preventing Taxane-Induced Neuropathy in Breast Cancer
In a German single-center trial (POLAR) reported in JAMA Oncology, Michel et al found that hand cooling and hand compression were associated with a reduced risk of taxane-induced neuropathy in women with primary breast cancer. Study Details In the trial, 101 patients enrolled at the National Center ...
Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?
With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which patients, however, might safely forgo the current recommendations and be safely followed with active...
In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers
The 2025 ASCO Gastrointestinal Cancers Symposium once again delivered a slate of high-impact studies spanning esophageal, gastric, hepatocellular, pancreatic, biliary tract, and colorectal malignancies. Experts in the field offered fresh perspectives on evolving standards of care, and investigators ...
Radiotherapy Alone Following Radical Hysterectomy for Cervical Cancer: Should It Remain the Standard of Care?
Results from the phase III NRG Oncology GOG-0263 trial—which tested the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma—indicated that the addition of...
Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD
Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual disease (MRD) after induction therapy, according to data presented during the 2024 American Society ...
Enfortumab Vedotin Plus Pembrolizumab Continues to Show Benefit in Metastatic Urothelial Carcinoma
In previously untreated patients with locally advanced or metastatic urothelial carcinoma, use of the antibody-drug conjugate enfortumab vedotin-ejfv in combination with the PD-1 inhibitor pembrolizumab continues to demonstrate a significant survival benefit over chemotherapy, according to updated...
Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer
Combining the PD-1 inhibitor nivolumab and chemotherapy, and following that regimen with response-adapted chemoradiation, may an effective treatment for advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma, according to a recent study published by Rosenberg et al in...
Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment
Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...
Top Picks From SABCS 2024
Among the high-quality abstract presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks our Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman...
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.”—Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Safety of Ceasing Combination Therapy After 2 Years in Patients With Renal Cell Carcinoma
Ceasing or pausing a combination of the immune checkpoint inhibitor nivolumab and the oral tyrosine kinase inhibitor (TKI) axitinib after 2 years may be safe among patients with metastatic renal cell carcinoma who achieved a positive response to this treatment, according to updated analysis of a...
Vimseltinib Approved by the FDA for Symptomatic TGCT
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. MOTION Trial Efficacy was...
Talazoparib Plus Enzalutamide Significantly Improves Overall Survival in Prostate Cancer Regardless of HRR Gene Status
Studies show that about one-quarter of advanced prostate cancers have alterations in DNA damage response genes involved directly or indirectly in homologous recombination repair (HRR) gene alterations, including BRCA1/BRCA2 genes, which can sensitize them to treatment with PARP inhibitors. Final...
Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer
The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E–mutant metastatic colorectal cancer, according to data presented at the 2025 ASCO Gastrointestinal ...
Primary Analysis of ZUMA-2: Bruton Tyrosine Kinase Inhibitor–Naive Relapsed or Refractory Mantle Cell Lymphoma
ZUMA-2 is a single-arm, multicenter, open-label phase II study that investigated leukapheresed adults with mantle cell lymphoma whose disease was refractory to or had relapsed after up to five prior lines of therapy, including anthracycline or bendamustine-containing chemotherapy; anti-CD20...
FDA Approves Brentuximab Vedotin With Lenalidomide and Rituximab for Relapsed or Refractory LBCL
The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL ...
Experimental Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer
The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E–mutant metastatic colorectal cancer, according to data presented at the 2025 ASCO Gastrointestinal ...
FDA Approves Mirdametinib for Neurofibromatosis Type 1
On February 11, the U.S. Food and Drug Administration approved mirdametinib (Gomekli), a kinase inhibitor, for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. ReNeu Trial...
Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup
An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 The phase III CheckMate 8HW trial compared the PD-1 inhibitor...
In Case You Missed It: Additional Studies of Interest From ASH 2024
A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...
Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials
The recently approved menin inhibitor revumenib is poised to improve the treatment of acute myeloid leukemia (AML), specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhibitors now in development—with their unique safety and activity profiles—suggest the...
Results From FIRE-4 Show Liquid Biopsy Can Detect RAS/BRAF-Mutated Metastatic Colorectal Cancer
The results from the phase III FIRE-4 randomized clinical trial show that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type–mutated metastatic colorectal cancer. The findings confirm the high clinical relevance of liquid biopsy performed at baseline before the start of...
Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL
A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary...
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
CheckMate 7FL: Neoadjuvant Immunochemotherapy in ER-Positive, HER2-Negative Breast Cancer
A phase III trial has shown adding the PD-1 inhibitor nivolumab to anthracycline- and taxane-based chemotherapy that patients receive ahead of surgery may improve breast cancer cure rates. CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer,...
Early-Stage Classic Hodgkin Lymphoma
“It isn’t the mountains ahead to climb that wear you out; it’s the pebble in your shoe.” —Muhammad Ali Long-term survival in early-stage classic Hodgkin lymphoma (cHL) was first made possible by the introduction of the mantle and inverted Y fields of radiotherapy in the 1960s. The addition of...
Some Patients With Low-Risk Ductal Carcinoma In Situ May Be Able to Avoid Surgery
Active monitoring appears to be a safe strategy for the management of some patients with low-risk ductal carcinoma in situ (DCIS), proving noninferior to guideline-concordant management of this patient population (ie, surgery with or without radiation therapy). After 2 years, the rate of invasive...
Getting a Lung Cancer Diagnosis Was Shocking
For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...
AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma
Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer,...
Imlunestrant Alone or With Abemaciclib: An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer
The investigational next-generation oral selective estrogen receptor degrader (SERD) imlunestrant improved progression-free survival both as monotherapy in patients with ESR1 mutations and in combination with the CDK4/6 inhibitor abemaciclib regardless of ESR1 mutational status in patients with...
Everolimus/Lanreotide vs Everolimus in Gastroenteropancreatic Neuroendocrine Tumors
A recent study found that a combination of the mTOR inhibitor everolimus and the hormone-blocking drug lanreotide extended progression-free survival compared with everolimus alone for people with some types of neuroendocrine tumors in the pancreas or gastrointestinal tract. The research will be...
FDA Approves Datopotamab Deruxtecan-dlnk for Advanced HR-Positive, HER2-Negative Breast Cancer
On January 17, the U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Datroway), a TROP-2–directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC1+, or...
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma
On January 16, the U.S. Food and Drug Administration (FDA) granted traditional approval to the Bruton’s tyrosine kinase inhibitor acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem...
FDA Approves Sotorasib With Panitumumab for KRAS G12C–Mutated Colorectal Cancer
On January 16, the U.S. Food and Drug Administration (FDA) approved the KRAS G12C inhibitor sotorasib (Lumakras) with the monoclonal antibody panitumumab (Vectibix) for adult patients with KRAS G12C–mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior ...
Therapeutic De-escalation in Breast Cancer: Can Omitting Axillary Surgery Match Survival While Improving Patient Outcomes?
Omitting axillary surgery may be an option for some patients with early-stage breast cancer, according to a study reported by Reimer et al in The New England Journal of Medicine. Previous studies, such as the SOUND trial, have indicated that avoiding an axillary procedure in patients with small...
